Zevra Therapeutics
ZVRA
29 hedge funds and large institutions have $103M invested in Zevra Therapeutics in 2015 Q2 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$14.8M |
| 2 |
BC
Broadfin Capital
New York
|
+$11.3M |
| 3 |
DA
DSC Advisors
Chicago,
Illinois
|
+$7.42M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$7.06M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$6.63M |
Top Sellers
ZVRA Hedge Fund Activity: Q2 2015 in Review
29 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2015, worth a combined $103M.
Buyers outnumbered sellers: 29 funds opened new ZVRA positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M.
- 29 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $103M of Zevra Therapeutics stock for Q2 2015.
- 29 funds opened new Zevra Therapeutics positions in Q2 2015 and 0 closed out, a net change of +29 holders.
- The largest Zevra Therapeutics buyer in Q2 2015 was Deerfield Management, an estimated $14.8M added.
Based on aggregated 13F filings for Q2 2015.